Core Viewpoint - A class action securities lawsuit has been filed against GSK plc, alleging securities fraud that affected investors between February 5, 2020, and August 14, 2022 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that GSK misrepresented the reasons for withdrawing Zantac from the market, stating it was based on available information and regulatory correspondence, while in reality, GSK had known about the source of NDMA for nearly 40 years [2]. - GSK assured investors that there was no evidence linking ranitidine therapy to cancer, which the lawsuit argues was materially false or misleading [2]. Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until April 7, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].

Core Viewpoint - GSK plc is facing a class action lawsuit related to the alleged misleading statements regarding the withdrawal of Zantac from the market and the company's knowledge of the potential cancer-causing agent NDMA [1][2]. Group 1: Allegations and Class Period - The class period for the lawsuit is from February 5, 2020, to August 14, 2022 [1]. - Allegations include that GSK misrepresented the reasons for removing Zantac, claiming it was based on available information and regulatory correspondence, while being aware of the NDMA source for nearly 40 years [1]. Group 2: Shareholder Actions - Shareholders who purchased GSK shares during the specified period are encouraged to register for the class action and can seek lead plaintiff status by April 7, 2025 [2]. - Registered shareholders will receive updates through portfolio monitoring software regarding the case's progress [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].

Core Viewpoint - Rosen Law Firm is reminding purchasers of GSK plc American Depositary Receipts (ADRs) of the upcoming lead plaintiff deadline for a class action lawsuit related to the company's alleged misleading statements regarding Zantac [1][2]. Group 1: Class Action Details - The class action pertains to GSK ADRs purchased between February 5, 2020, and August 14, 2022, with a lead plaintiff deadline set for April 7, 2025 [1][2]. - Investors who purchased GSK ADRs during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Allegations Against GSK - The complaint alleges that GSK misrepresented the reasons for withdrawing Zantac from the market, claiming it was based on available information and regulatory correspondence, while in reality, GSK had known about the source of NDMA for nearly 40 years [4][5]. - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which was later revealed to be misleading as the company had concealed an internal study implicating its liability [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3].

Core Viewpoint - A class action securities lawsuit has been filed against GSK plc, alleging securities fraud that affected investors between February 5, 2020, and August 14, 2022 [1] Group 1: Lawsuit Details - The lawsuit claims that GSK misled investors regarding the removal of Zantac from the market, stating it was based on available information and regulatory correspondence [2] - GSK allegedly assured investors that there was no evidence linking ranitidine therapy to cancer, which was inconsistent with the company's prior knowledge of the source of NDMA for nearly 40 years [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=130540&from=4CLASS PERIOD: February 5, 2020 to August 14, 2022ALLEGATION ...

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=129530&wire=4 GSK i ...

Core Viewpoint - GSK's fourth quarter 2024 financial results were released on February 5, showing a mixed market reaction primarily due to the underperformance of its vaccine franchise [1] Financial Performance - GSK reported its financial results for the fourth quarter of 2024, which were characterized by a relatively weak performance in its vaccine segment [1]

Ken Griffin's hedge fund Citadel has placed a £305 million ($390 million) short bet against GSK PLC GSK, marking the largest wager against the UK pharma giant in over a decade, reported the Financial Times. The position, disclosed to the UK's Financial Conduct Authority, amounts to 0.51% of GSK's outstanding shares.GSK's Rally Faces A Reality CheckGSK stock has climbed 8.20% in the past month, fueled by a £2 billion ($2.5 billion approx.) stock buyback and strong HIV and cancer drug sales. Yet, it still tra ...

SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all purchasers of the American Depository Receipts ("ADRs") of GSK PLC (NYSE: GSK) between February 5, 2020 and August 14, 2022. GSK is a global pharmaceutical company that develops, manufactures, and markets vaccines and medicines worldwide.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating A ...

NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=129242&wire=4GSK in ...